Scarica l'app Stockscreener
0.00
100.00%
-76.01
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$76.01
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
0.00
Capitalizzazione di mercato:
$16.97B
Reddito:
$4.13B
Utile/perdita netta:
$543.90M
Rapporto P/E:
0.00
EPS:
2.41
Flusso di cassa netto:
$957.20M
1 W Prestazione:
-100.00%
1M Prestazione:
-100.00%
6M Prestazione:
-100.00%
1 anno Prestazione:
-100.00%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$0.00
$0.00
Portata 52W:
$0.00
$76.07
Hologic Inc Stock (HOLX) Company Profile
Nome
Hologic Inc
Settore
Industria
Telefono
(508) 263-2900
Indirizzo
250 CAMPUS DRIVE, MARLBOROUGH, MA
Compare HOLX vs ISRG, BDX, ALC, MDLN, RMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HOLX
Hologic Inc
|
0.00 | 16.97B | 4.13B | 543.90M | 957.20M | 2.41 |
ISRG
Intuitive Surgical Inc
|
438.10 | 155.76B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
147.63 | 40.30B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
67.78 | 33.13B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
37.01 | 31.37B | 29.14B | 1.07B | 1.05B | 1.1956 |
RMD
Resmed Inc
|
208.05 | 30.31B | 5.54B | 1.52B | 1.74B | 10.37 |
Hologic Inc Stock (HOLX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-12 | Downgrade | Argus | Buy → Hold |
| 2026-01-05 | Downgrade | Evercore ISI | Outperform → In-line |
| 2025-11-21 | Downgrade | BNP Paribas Exane | Outperform → Neutral |
| 2025-10-07 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2025-08-18 | Aggiornamento | Argus | Hold → Buy |
| 2025-08-06 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-07-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-05-27 | Reiterato | Needham | Hold |
| 2025-03-03 | Downgrade | Argus | Buy → Hold |
| 2025-02-06 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-02-03 | Downgrade | Needham | Buy → Hold |
| 2024-12-13 | Iniziato | Wolfe Research | Peer Perform |
| 2024-12-10 | Iniziato | Jefferies | Hold |
| 2024-12-10 | Reiterato | Needham | Buy |
| 2024-10-01 | Downgrade | Citigroup | Buy → Neutral |
| 2024-06-27 | Iniziato | Stephens | Overweight |
| 2024-04-03 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-07-14 | Aggiornamento | Needham | Hold → Buy |
| 2022-12-07 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2022-10-13 | Iniziato | Mizuho | Buy |
| 2022-07-20 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-07-20 | Iniziato | UBS | Neutral |
| 2022-07-18 | Downgrade | BTIG Research | Buy → Neutral |
| 2022-04-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-04-04 | Downgrade | Evercore ISI | Outperform → In-line |
| 2021-12-15 | Downgrade | Citigroup | Buy → Neutral |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-10-14 | Iniziato | Redburn | Neutral |
| 2021-07-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2020-11-20 | Downgrade | Needham | Buy → Hold |
| 2020-11-05 | Reiterato | Needham | Buy |
| 2020-06-30 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2020-06-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2020-04-30 | Reiterato | Needham | Buy |
| 2020-04-30 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-04-07 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-03-27 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2020-01-13 | Reiterato | Needham | Buy |
| 2020-01-08 | Iniziato | Wells Fargo | Equal Weight |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2020-01-02 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-09-26 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-08-01 | Reiterato | Needham | Buy |
| 2019-05-02 | Reiterato | Needham | Buy |
| 2019-01-31 | Reiterato | Needham | Buy |
| 2019-01-02 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2018-10-09 | Iniziato | UBS | Neutral |
| 2018-09-13 | Downgrade | BofA/Merrill | Buy → Neutral |
Mostra tutto
Hologic Inc Borsa (HOLX) Ultime notizie
Hologic, Inc. (HOLX) Stock Analysis: Navigating Steady Growth In The Healthcare Sector - DirectorsTalk Interviews
OCONNOR, A Distinct Business Unit Of UBS ASSET MANAGEMENT AMERICAS (LLC) HOLX Holdings History - GuruFocus
Absolute Gestao de Investimentos Ltda.'s Hologic Inc(HOLX) Holding History - GuruFocus
The Official Home of the Women's Tennis Association | WTA Tennis - WTA Tennis
Hologic, Inc. (HOLX) Stock Analysis: Steady Growth With A Strong Focus On Women's Health - DirectorsTalk Interviews
CIBRA Capital Ltd's Hologic Inc(HOLX) Holding History - GuruFocus
How Data Can Serve as a Lifeline for Women’s Health - Hologic
Laura Friedman from California’s 30th District makes transactions in Hologic, Inc. - Investing.com Nigeria
Laura Friedman from California’s 30th District makes transactions in Hologic, Inc. By Investing.com - Investing.com South Africa
Investors heavily search Hologic, Inc. (HOLX): Here is what you need to know - MSN
Hologic stock (US4364401012): Analyst hold consensus with limited upside - AD HOC NEWS
Hologic, Inc. (HOLX) is a trending stock: Facts to know before betting on it - MSN
Hologic stock (US4364401012): Blackstone and TPG acquisition nears completion - AD HOC NEWS
Hologic Tells NH Justices It's One Org.; State Pushes Back - Law360
Body Composition Analyzers Market is expected to Hit US$ 1.25 - openPR.com
Hologic stock (US4364401012): Joins S&P SmallCap 600 ahead of May 14 - AD HOC NEWS
New Hampshire Justices Dissect Hologic’s Business Tax Method - Bloomberg Law News
Human Papillomavirus Testing Market Witnesses Asia-Pacific & North America Growth | Roche, Qiagen, Hologic - openPR.com
Primary Care Poc Diagnostics Market Is Going to Boom | Cepheid, Hologic - openPR.com
OM1 Supports 650,000 Patient Real-World Regulatory Submission for FDA Approval of Hologic's Aptima HPV Assay - Yahoo Finance
Hologic, Inc. (HOLX) Stock Analysis: Steady Growth With Limited Upside Potential - DirectorsTalk Interviews
Hologic stock (US4364401012): Takeover deal and women’s health focus in focus - AD HOC NEWS
Hereditary Cancer Testing Market Will Generate Booming Growth - openPR.com
Body Composition Analyzers Market Size Accelerating at 11.2% - openPR.com
Top medtech executive moves in 2026 - MedTech Dive
Hologic Nurse Advocate Program: Support for Heavy Periods & Fibroids - Hologic
GW&K Investment Management, LLC's Hologic Inc(HOLX) Holding History - GuruFocus
Hologic, Inc. (HOLX) Stock Analysis: Exploring the Healthcare Giant’s Strong Position with Limited Upside - DirectorsTalk Interviews
Blackstone & TPG Complete Hologic Acquisition, Appoint Joe Almeida as CEO - Digital Health News
Vanguard owns 16.7M Hologic shares in filing (HOLX) — 7.49% stake disclosed - Stock Titan
Hologic Stock (US4364401012): Earnings Release Scheduled for Today - AD HOC NEWS
MSN Money - MSN
HPV Testing Market Size Expected to Reach $18.6 Billion at 11.2% - openPR.com
Is trending stock Hologic, Inc. (HOLX) a buy now? - MSN
Hologic, Inc. (HOLX) Stock Analysis: Steady Healthcare Innovator with Limited Upside Potential - DirectorsTalk Interviews
Hologic Stock Rises as Report Says Blackstone and TPG in Advanced Takeover Talks - MSN
Hologic Inc Azioni (HOLX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.10%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):